clinical dataGSK and Roche Chinese ADC bets deliver positive phase 3 data in SCLCTwo B7-H3-targeted antibody-drug conjugates licensed from Chinese biotechs have now delivered positive phase 3 survival data in relapsed small-cell lung cancer, strengthening the oncology bets GSK and … more ➔
BioNTech SEOncologyBioNTech adds clinical weight to its oncology pivot at WCLC 2026New data from the World Conference on Lung Cancer in Seoul are giving BioNTech’s oncology strategy more substance beyond its mRNA platform. Gotistobart has shown a marked survival benefit in previously … more ➔
fundraisingAllogenetics adds €3.8M for rejection-resistant donor lungsHanover-based Allogenetics has raised €3.8 million in a Pre-Series A round to advance ALG-115, an ex vivo gene therapy for donor lungs, through IND-enabling studies and toward a first-in-human trial … more ➔
StrategySimris steps on Heidelberg Pharma’s toes with amanitin pivotSimris Group is making amanitin-based ADCs the center of its strategy under former Heidelberg Pharma CEO Andreas Pahl — less than two months after hiring the executive who helped build Heidelberg Pharma’s … more ➔
EthrisInfectious diseaseEIB backs Ethris with €30 million for broad-spectrum antiviral mRNAThe European Investment Bank (EIB) is providing German Ethris with €30 million to advance clinical development of its mRNA-based antiviral candidate ETH47. The Munich-based RNA specialist has been … more ➔
CDMONorthway opens €61M Vilnius plant built for personalized medicineCDMO company Northway Biotech has opened a €61 million cell therapy and personalized medicine center in Vilnius that is being qualified for GMP manufacturing, and the company says it expects a manufacturing … more ➔
startupsConnecta raises €3.1M for Fragile X syndrome Phase 2The Barcelona-based biotech will use the financing to complete a 30-patient Phase 2a study of its lead candidate CTH120, with the first efficacy data expected in mid-2027. more ➔
clinical dataTeitur Trophics reports positive phase 1 data for Parkinson’s peptideDanish biotech Teitur Trophics completed its phase 1 study and said its experimental Parkinson’s disease treatment TT-P34 was safe and reached the central nervous system, supporting plans to move the … more ➔
M&ALeyden Labs reveals RIGImmune acquisition with Phase 1 dataDutch biotech Leyden Labs has reported positive Phase 1 results for intranasal RIG-101 and disclosed that it acquired the drug’s developer, RIGImmune, earlier this year. more ➔
Drug deliveryInside exosomes: Nature’s drug carriersNext-gen, effective payloads – from AI-designed small molecules to RNA-based therapeutics and gene therapies – have revolutionized medicine. Yet, the main hurdle remains targeted delivery: avoiding … more ➔
BioNTech SE
Ethris
